Novonesis AI Stock Analysis
Want to see NVZMY full AI Analyst Report?
Novonesis (NVZMY) AI Stock Analysis
Novonesis
(Other OTC:NVZMY)
The score is driven primarily by solid underlying operating profitability and positive cash generation, tempered by a recent TTM net loss and volatility in key financial metrics. Technicals are mildly supportive but not strongly bullish. Valuation is a headwind due to a high P/E, while the latest earnings call adds support via reaffirmed growth/margin guidance despite noted free-cash-flow pressure and a delayed recovery in U.S. dietary supplements.
Novonesis (NVZMY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $30.88B
- Dividend Yield
- 0.24%
- Average Volume (3M)
- 26.39K
- Price to Earnings (P/E)
- 40.2
- Beta (1Y)
- 0.05
- Revenue Growth
- 10.90%
- EPS Growth
- 30.98%
- Country
- US
- Employees
- 11,641
- Sector
- Basic Materials
- Sector Strength
- 61
- Industry
- Chemicals - Specialty
Novonesis Business Overview & Revenue Model
Company Description
Established in 1925 and based in Bagsvaerd, Denmark, Novozymes A/S is a global provider of biological solutions, specializing in the development and sale of industrial enzymes, microorganisms, and probiotics. The company's reach extends international...
How the Company Makes Money
Novonesis makes money primarily by selling bio-based ingredients and solutions—most notably enzymes and microbial cultures/biocultures—to business customers (B2B) worldwide. Revenue is generated through commercial supply agreements where customers pu...
Novonesis Earnings Call Summary
The call was predominantly positive. Novonesis reported solid 7% organic growth, strong margins, broad-based Food & Beverages and Energy momentum, continued innovation, completed strategic investments and confirmed its full-year outlook. The main challenges were the North American dietary supplements downturn, declines in Plant and Tech, elevated CapEx and lower free cash flow, but management expressed confidence in recovery initiatives and the long-term growth trajectory.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Novonesis confirmed full-year 2026 organic sales growth guidance of 7% to 8%, with fourth quarter organic sales growth expected to be in the range of high-single digit and growth mainly volume-driven, supported by a good 1 percentage point contribution from synergies and around 1.5 percentage point from pricing, while exiting certain countries is expected to have a close to 1 percentage point negative effect; adjusted EBITDA margin is expected to be at the higher end of the 37% to 38% range, Food & Health Biosolutions is expected to deliver organic sales growth around the higher end of the group range, Planetary Health Biosolutions around the lower end of the group range, Human Health to slightly decline, Advanced Health & Nutrition to contribute positively led by HMO and supported by Advanced Protein Solutions, and U.S. Dietary Supplements to recover in the second half of 2027; Agricultural, Energy and Tech growth is expected to be broad-based, led by energy and agricultural, CapEx is expected to be towards the higher end of the 12% to 14% of sales, net debt-to-EBITDA ratio is expected to be around 1.8x at year-end, and a noncash revaluation gain on step acquisition of around EUR 35 million is expected in the fourth quarter.
Novonesis Financial Statement Overview
Summary
Operating profitability and cash generation are solid (TTM gross margin ~55%, EBITDA margin ~30%, positive operating cash flow ~1.24B and free cash flow ~0.70B). The main offsets are weaker earnings quality (TTM net loss despite healthy operating margins) and volatility in revenue, leverage history, and free cash flow.
Income Statement
62PositiveBalance Sheet
58NeutralCash Flow
67Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.39B | 4.16B | 513.65M | 17.90B | 17.55B | 14.95B |
| Gross Profit | 2.47B | 2.24B | 242.45M | 9.72B | 9.58B | 8.62B |
| EBITDA | 1.49B | 1.39B | 1.21B | 5.47B | 6.12B | 5.39B |
| Net Income | -203.32M | 583.60M | 40.97M | 3.02B | 3.68B | 3.15B |
Balance Sheet | ||||||
| Total Assets | 16.83B | 16.35B | 15.20B | 28.39B | 27.98B | 24.77B |
| Cash, Cash Equivalents and Short-Term Investments | 465.50M | 295.60M | 284.00M | 1.16B | 1.11B | 1.04B |
| Total Debt | 3.18B | 22.45B | 1.80B | 7.73B | 6.95B | 482.00M |
| Total Liabilities | 5.61B | 5.49B | 4.02B | 14.04B | 13.76B | 12.56B |
| Stockholders Equity | 11.22B | 10.86B | 11.18B | 13.98B | 13.84B | 11.83B |
Cash Flow | ||||||
| Free Cash Flow | 699.76M | 750.70M | 660.10M | 2.10B | 1.12B | 2.82B |
| Operating Cash Flow | 1.24B | 1.22B | 1.02B | 4.15B | 4.01B | 4.06B |
| Investing Cash Flow | -623.97M | -1.97B | -199.70M | -2.13B | -2.67B | -2.75B |
| Financing Cash Flow | -442.22M | 753.30M | -703.20M | -1.89B | -1.25B | -1.59B |
Novonesis Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVZMY, the sentiment is Neutral. The current price of 66.17 is below the 20-day moving average (MA) of 68.89, below the 50-day MA of 67.09, and above the 200-day MA of 62.60, indicating a neutral trend. The MACD of -0.24 indicates Positive momentum. The RSI at 44.56 is Neutral, neither overbought nor oversold. The STOCH value of 17.48 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NVZMY.
Novonesis Peers Comparison
Overall Rating
EMN65Neutral
SHW65Neutral
NVZMY63Neutral
ESI62Neutral
PPG62Neutral
SCL55Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 65Neutral | $7.13B | 11.00 | 10.63% | 5.39% | 0.40% | -6.58% | |
| 65Neutral | $83.73B | 31.57 | 63.49% | 0.92% | 7.03% | 5.95% | |
| 63Neutral | $30.89B | 40.23 | 6.17% | 0.24% | 10.90% | 30.98% | |
| 62Neutral | $7.90B | 38.53 | 7.39% | 0.98% | 39.62% | -14.83% | |
| 62Neutral | $27.12B | 17.44 | 19.05% | 2.36% | 6.39% | 27.29% | |
| Sector * | 61Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
| 55Neutral | $1.50B | 347.63 | 0.36% | 2.39% | 10.02% | -90.50% |
* Basic Materials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NVZMY | Novonesis A/S - Adr | 66.17 | 5.88 | 9.75% | |
| EMN | Eastman Chemical Company | 62.36 | 8.67 | 16.16% | |
| PPG | Ppg Industries, Inc. | 122.78 | 29.87 | 32.15% | |
| SHW | Sherwin-Williams | 346.60 | 21.66 | 6.66% | |
| SCL | Stepan Company | 66.05 | 24.68 | 59.64% | |
| ESI | Element Solutions | 32.57 | 9.80 | 43.03% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
